Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.66 |
| ▸ | CDK8 | P49336 | 8/20 | 0.55 |
| ▸ | AXL | P30530 | 3/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.53 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | CDK7 | P50613 | 2/20 | 0.46 |
| ▸ | PLK4 | O00444 | 2/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | INSR | P06213 | 2/20 | 0.46 |
| ▸ | CDK1 | P06493 | 2/20 | 0.46 |
| ▸ | ROS1 | P08922 | 2/20 | 0.46 |
| ▸ | FER | P16591 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | MARK3 | P27448 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22978455 | 0.80 | RIPK1 (1.00) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL4831501 | 0.78 | CDK8 (0.81) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL14620970 | 0.77 | RIPK1 (0.62) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL23655689 | 0.77 | CDK8 (0.56) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL31064962 | 0.76 | RIPK1 (0.69) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL4165829 | 0.76 | RIPK1 (0.69) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL294108 | 0.75 | CDK8 (0.55) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL11968477 | 0.75 | CDK8 (0.55) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL926536 | 0.75 | CDK8 (0.55) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL297772 | 0.75 | CDK8 (0.55) | RIPK1CDK8AXLPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4421075-A1 | PROCESS FOR THE PREPARATION OF VENETOCLAX AND INTERMEDIATES USED THEREIN | KRKA, d.d., Novo mesto (SI) | 2024-08-28 | — | — | EP | claimed |
| CN-118373820-A | Continuous preparation method and continuous synthesis device of 5-hydroxy-7-azaindole | 峰成医药科技(天津)有限公司 | 2024-07-23 | — | — | CN | claimed |
| CN-117903129-A | Synthesis method of valnemulin intermediate | 无锡紫杉药业股份有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-117126157-A | Preparation method of 5-hydroxy-7-azaindole | 舞阳威森生物医药有限公司 | 2023-11-28 | — | — | CN | claimed |
| CN-115197130-B | Aryl urea derivative and preparation method and application thereof | 安徽医科大学 | 2023-06-27 | — | — | CN | claimed |
| US-20230159524-A1 | METHODS FOR SYNTHESIZING N-(PHENYLSULFONYL)BENZAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-05-25 | — | — | US | claimed |
| CN-113880834-B | Synthesis method of N- (phenylsulfonyl) benzamide compound and intermediate thereof | 苏州亚盛药业有限公司 | 2023-01-20 | — | — | CN | claimed |
| CN-115197130-A | Aryl urea derivative and preparation method and application thereof | 安徽医科大学 | 2022-10-18 | — | — | CN | claimed |
| CN-115141197-A | 3-aromatic heterocyclic substituted phenyl derivative and preparation method and application thereof | 安徽医科大学 | 2022-10-04 | — | — | CN | claimed |
| WO-2022002178-A1 | METHODS FOR SYNTHESIZING N-(PHENYLSULFONYL)BENZAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-01-06 | — | — | WO | claimed |
| CN-113880834-A | Synthesis method of N- (phenylsulfonyl) benzamide compound and intermediate thereof | 苏州亚盛药业有限公司 | 2022-01-04 | — | — | CN | claimed |
| CN-112939968-A | Preparation method of 5-hydroxy-7-azaindole | 南通雅本化学有限公司 | 2021-06-11 | — | — | CN | claimed |
| CN-110922404-A | Process for preparing 5-hydroxy-7-azaindoles | 南京正济医药研究有限公司 | 2020-03-27 | — | — | CN | claimed |
| CN-104370905-B | The synthesis of Bcl-2 AB combined inhibitor T-199 | NANJING ACESYS PHARMATECH CO., LTD. (CN) | 2016-06-01 | — | — | CN | claimed |
| CN-104370905-A | Synthesis of Bcl-2 inhibitor ABT-199 | NANJING ACESYS PHARMATECH CO LTD | 2015-02-25 | — | — | CN | claimed |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12583853-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-24 | — | — | US | disclosed |
| WO-2004009601-A1 | AZAINDOLE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2003064413-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | WO | disclosed |
| CN-1346271-A | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA UK LTD (SE) | 2002-04-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159524-A1 | METHODS FOR SYNTHESIZING N-(PHENYLSULFONYL)BENZAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | CTPS2, CDK2, PAICS | RIPK1 1226/4885CDK8 8/4885AXL 2880/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | RIPK1 1579/4885CDK8 3496/4885AXL 2604/4885 |
| US-12583853-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | BCL3, BCL9, BCL6 | RIPK1 1915/4885CDK8 698/4885AXL 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.